According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM) is A$53.8 M. In 2022 the company made a revenue of -A$47.54 M a decrease over the revenue in the year 2021 that were of A$20.44 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.